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Use of the anti-tumour antibiotic actinomycin D is associated with development of hepatotoxicity, particularly in young children.
A paucity of actinomycin D pharmacokinetic data make it challenging to develop a sound rationale for defining dosing regimens
in younger patients. The study aim was to develop a physiologically based pharmacokinetic (PBPK) model using a combination of
data from the literature and generated from experimental analyses.
METHODS
Assays to determine actinomycin D Log P, blood:plasma partition ratio and ABCB1 kinetics were conducted. These data were
combined with physiochemical properties sourced from the literature to generate a compound file for use within the modelling-
simulation software Simcyp (version 14 release 1). For simulation, information was taken from two datasets, one from 117 pa-
tients under the age of 21 and one from 20 patients aged 16–48.
RESULTS
The final model incorporated clinical renal and biliary clearance data and an additional systemic clearance value. The mean AUC0-26h
of simulated subjects was within 1.25-fold of the observed AUC0-26h (84 ng h ml
1 simulated vs. 93 ng h ml1 observed). For the
younger age ranges, AUC predictions were within two-fold of observed values, with simulated data from six of the eight age/dose
ranges falling within 15% of observed data. Simulated values for actinomycin D AUC0-26h and clearance in infants aged 0–12 months
ranged from 104 to 115 ng h ml1 and 3.5–3.8 l h1, respectively.
CONCLUSIONS
The model has potential utility for prediction of actinomycin D exposure in younger patients and may help guide future
dosing. However, additional independent data from neonates and infants is needed for further validation. Physiological
differences between paediatric cancer patients and healthy children also need to be further characterized and incorporated
into PBPK models.© 2016 The Authors. British Journal of Clinical Pharmacology published
by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.
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C. Walsh et al.WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT?• Treatment of children with cancer with actinomycin D is associated with hepatotoxicity, particularly in younger patients.
• Limited information currently exists relating to the pharmacokinetics of actinomycin D in either adult or childhood cancer patient
populations.
• Current actinomycin D dosing guidelines for infants and younger children vary between clinical trial protocols.
WHAT THIS STUDY ADDS
• We generated essential physicochemical property data for actinomycin D, facilitating the generation of a compound file for
PBPK model development.
• A PBPK model for actinomycin D was developed, with the potential for prediction of actinomycin D exposure in infants and
younger children, which may provide a useful tool to guide future dosing in these challenging patients.Introduction
Actinomycin D (Act D) is a polypeptide antibiotic that has
been used in the treatment of various types of cancer for over
40 years. It functions by binding to DNA in a guanine-
dependent manner thus inhibiting RNA polymerase and
preventing DNA transcription [1]. Act D is predominantly
administered to paediatric patients with Wilms’ tumour,
Ewing’s sarcoma or rhabdomyosarcoma, often in combina-
tion with other chemotherapeutics including vincristine
and cyclophosphamide. These three cancers account for
roughly 10% of all cancers seen in children in the United
States. While Ewing’s sarcoma occurs predominantly in
teens, both Wilms’ tumour and rhabdomyosarcoma are
prevalent in younger children, with Wilms’ tumour affecting
almost exclusively patients under 6 years of age. Treatment
with Act D is associated with a type of hepatotoxicity known
as sinusoidal obstructive syndrome (SOS) (formerly called
veno-occlusive disease) [2]. SOS is caused by the blockage of
the small blood vessels of the liver following chemotherapy
or bone marrow transplant, with symptoms including fever,
anaemia and thrombocytopenia. Age appears to be a risk
factor for the development of SOS; with patients under three
years of age exhibiting a 15% chance of developing the
disease compared to a 4% likelihood in patients over three
years of age [3]. There is also evidence to suggest that dose
intensity of act D may be linked to incidence of SOS, with
one study showing that a dose reduction from 60 μg ml1 to
40 μg ml1 led to fewer toxic events [4].
Clinical investigations into the pharmacokinetics (PKs) of
Act D have been limited, with a small published PK study
(n = 3) in adult patients [5] and a more recent study of Act
D, methotrexate and etoposide in combination (n = 35 adult
patients) [6]. The PK of Act D is typically described by a
multicompartmental model, reflecting a rapid distribution
phase into tissues and a long terminal phase half-life [5]. This
long terminal phase reflects extensive distribution into many
tissues, including skeletal muscle, kidney, lung and liver, with
correspondingly long tissue half-lives seen in animal studies
[7]. Low cerebrospinal fluid (CSF) concentrations after IV
administration [5] as well as poor brain uptake in animal
studies [7] indicate poor central nervous system (CNS)
penetration. Act D does not bind strongly to red blood cells,
but has been shown to concentrate in nucleated blood cells
such as lymphocytes and granulocytes. Elimination is
thought to be mainly via renal and biliary excretion, with2 Br J Clin Pharmacol (2016) •• ••–••approximately 35% of an administered dose eliminated in
the urine and faeces after nine days. Metabolism is negligible,
with 1–4% of an IV dose converted to monolactone metabo-
lites [5].
There has been a greater interest in the PK of Act D in
young patients, with larger sized published studies in
children [8–10]. These paediatric studies were carried out
mainly due to concerns regarding the correlation between
younger age and SOS in this population and the very limited
amount of published data available from adult cancer
patients. While population PK models have been developed
for Act D [8], the associated studies enrolled very few patients
under the age of one year and none who were preterm or
immediately post-natal. Given the risk factor of younger age
in the development of SOS, it is important that consideration
is given to how children under the age of three years are dosed
with Act D, particularly in the case of neonates and infants.
While malignancies in infants only represent approximately
10% of all cancers diagnosed in children under 15, Wilms’
tumour has a relatively high incidence rate within the infant
cancer patient population [11]. Development of a rationale
for dose selection in these very young patients should aim
to maximize anticancer efficacy while minimizing the risk
of toxicity.
No current consensus exists on the most appropriate dose
and dosing regimen for Act D in younger children, with dose
reductions implemented for children under 6 months, under
12 months or under 3 years, depending on geographic region
(e.g. Europe or USA) and study protocol [12]. Previous clinical
trials performed in the UK have incorporated dose adjust-
ments from a standard dose of 1.5 mg m2 to 25 μg kg1 from
birth to 6 months of age and 1.0 mg m2 from 6 months to
1 year or less than 10 kg body weight [13]. Such age- or
weight-based cut-off points can lead to instances where, once
a threshold age or weight for a certain dose is reached, a
patient will potentially receive a markedly increased dose
following a relatively minor increase in body weight and/or
age. Dosing recommendations for Act D have been revised
on various occasions following concerns of under-dosing or
toxicity. However, no real scientific rationale currently exists
for deciding the optimal dose of Act D in very young patients,
with dose modifications based on caution and assumptions
rather than a sound understanding of the disposition of Act
D in these patients. Given the relative lack of clinical pharma-
cokinetic data available to guide dosing, the use of modelling
and simulation methodologies offers an opportunity to
Actinomycin D PBPK model for children with cancerpredict the PK effects of various Act D doses and dosing
regimens in different paediatric age ranges.
Physiologically based pharmacokinetic (PBPK) modelling
and simulation is a method of PK analysis that can be used to
predict the concentration–time course of a drug and its
associated PK parameters using physiochemical and in vitro
drug information as the basis for the model. In such a multi-
compartmental approach, major organs and tissues are
represented by individual compartments which are arranged
anatomically. In addition, nested models can be incorporated
that describe the processes occurring in a particular organ.
Nested models of the liver [14] and the kidney [15] may
incorporate the metabolic processes of transporters, CYP
enzymes and UGT enzymes, as well as the filtration and
permeation of solutes into urine or bile. Commercially
available PBPK software programs include virtual patient
populations, which can be used to predict the impact of
changing anatomy and physiology with age, in the case of
paediatrics [16, 17], or pathophysiology of specific organs,
in the case of hepatic or renal impairment [18]. The use of
PBPK modelling in the prediction of anticancer drug PKs in
children has been described previously for methotrexate
and etoposide [19, 20].
The aim of the current study was to develop a mechanisti-
cally based PBPK model for Act D in paediatric patients, with
a view to facilitating the rational prediction of drug exposure
in age ranges for which there are currently limited or no data
to inform future dosing strategies.Methods
Reagents
4-methoxyphenol,m-Cresol, 1-naphthol, thymol, diphenyl
ether, DMSO, Rosswell Park Memorial Institute (RPMI) 1640
medium with L-glutamine, zinc sulphate and Act D were
purchased from Sigma-Aldrich (Poole, UK). Sodium nitrate
was purchased from ReAgent (Cheshire, UK). Acetonitrile
was provided by Fischer Scientific (Loughborough, UK).
Foetal bovine serum and phenol red free Dulbecco’s modi-
fied eagle medium (DMEM) were purchased from Gibco
(Paisley, Scotland).
Drug/molecular target names used here are in accordance
with the BJP’s Guide to Receptor and Channels [21].
Log P
Themethod for the generation of Log P values by high perfor-
mance liquid chromatography (HPLC) was adapted from that
described by Zhao et al. [22]. Briefly, Log P correlates with the
retention time of a compound by a solid phase C18 column.
More lipophilic compounds partition more strongly onto
the column and so are retained for a greater length of time
than less lipophilic ones. By using compounds with known
Log P values, a standard curve can be determined and the
Log P of a compound of interest obtained by interpolation.
A Waters HPLC system, linked to an Agilent fluorescence
detector, was used along with a Luna 5 μ C18 50 × 2.0 mm
HPLC column preceded by a guard column (Phenomenex,
Macclesfield, UK). Compounds with published Log P values
(phenol, dexamethasone, chloramphenicol and verapamil)and sodium nitrate (a compound with a retention time of
zero) were included as standards in the assay. Solutions of
each of the standards (10 mM) were prepared in dimethyl
sulfoxide (DMSO) and a 1 mg ml1 solution of Act D was pre-
pared inmethanol. The sample holder for the HPLCwas set at
25 °C in order to prevent freezing of the DMSO during the
run. The mobile phase consisted of deionized water and ace-
tonitrile with a constant gradient of 40–60%, respectively.
Prior to each run the column was equilibrated to the run-
ning conditions for 10 minutes, with the flow rate set to
0.5 ml min1. A 20-μl aliquot of each sample was injected
into the column and its retention time measured relative to
that of the sodium nitrate peak. Peaks were analysed using
Empower software (Waters, Wilmslow, UK).Transporter kinetics
Previous work on the affinity of Act D for drug transporters
was used to guide the in vitro assessment of transporter
kinetics [23]. In addition, the ability of the generated model
to be extrapolated to other populations was assessed by
attempting to predict Act D PK in adults, a population in
which limited published data exist.
Polarized Madin-Darby canine kidney (MDCKII) cell line
wild-type and cells transfected with ABCB1 (MDR1) were ob-
tained from Dr. A.H. Schinkel (Amsterdam, the Netherlands).
Cells were cultured in RPMI 1640 medium supplemented
with L-glutamine and 10% foetal bovine serum, grown at
37 °C, 5% CO2 in a humidified incubator and were routinely
screened for mycoplasma.
For drug transport experiments, 12-mm Corning Transwell
polycarbonate membrane cell culture inserts with 0.4-μm pores
were used (Sigma Aldrich, UK). Cells (passage 8–12) were seeded
at 1.4 × 104 cellsml1 in growthmedium and grown on filter for
5 days before the experiment was performed, with medium
being changed every 24 hours. Fresh solutions of Act D were
made at 0.1, 1, 10 and 100 μM in phenol red-free Dulbecco’s
modified Eagle’s medium (DMEM). Growth medium was
aspirated from both the apical and basal compartments, and
the cells were washed twice with pre-warmed phosphate-
buffered saline adjusted to pH 7.4. Act D solutions (1.55 ml)
were added to the basal chamber of their respective wells and
phenol red-free DMEM (0.5 ml) was added to the apical side of
the monolayers. A 50-μl sample from the initial Act D donor
solutions was added to a 96-well plate to be analysed alongside
the post-assay donor and receiver samples. Lucifer yellow
(60 μM) was added as a paracellular control to test for the
formation of a fully confluent monolayer. A limit of 2% Lucifer
yellow movement was set as the cutoff with the results for any
wells exceeding that threshold being rejected.
After 1 h, a 50-μl aliquot of the experimental medium was
taken from both the apical and basal chambers of each well
and transferred to a 96-well plate for dilution (1:2 with
phenol red-free DMEM) and quantification of Act D
concentrations by liquid chromatography–mass spectrome-
try (LC–MS). An additional 50-μl sample was taken and added
to a 384-well black plate for analysis of Lucifer yellow
permeation. Analysis was carried out using a Luna 3 μ C8 (2)
Mercury 20 × 4 mm column and a mobile phase consisting
of: A acetate buffer (pH 4) and B methanol. After 10 min of
conditioning at 35% A and 65% B, injections of 50 μl wereBr J Clin Pharmacol (2016) •• ••–•• 3
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described [24].
The rate of efflux (μM min1/106 cells) due to MDR1 was
determined by subtracting the rate of flux seen across the
MDCKII-WT cells from the flux across the MDCKII-MDR1
cells. Cell counts were determined by re-suspending the cells
using trypsin and counting using a haemocytometer.Blood:plasma partitioning
An extraction solution of 1:1 deionized water and acetonitrile
with 0.1% zinc sulphate was prepared on the day of the
experiment and Act D solutions of 4, 20 and 100 μgml1 were
prepared in saline. All experiments were performed in
triplicate. An aliquot of 180 μl whole blood from a healthy
donor was added to 20 μL of each Act D solution (final
concentrations 0.4, 2 and 10 μg ml1) in Eppendorf tubes,
followed by gentle rotation for 1 min before transfer to an
incubator (Infors HT Multitron Standard, Infors AG, Basel)
at 37 °C for 1 h and 40 μl of plasma was transferred to a new
Eppendorf and mixed with 40 μl of fresh blood.
For the blood samples, 40 μl of blood was transferred to a
new Eppendorf and mixed with 40 μl blank plasma. All
samples were then mixed with 160 μl of the extraction
solution and frozen at 80 °C for 1 h. Samples were then
centrifuged at 2000 g and 4 °C for 1 h and 100 μl of superna-
tant from each sample was transferred to HPLC vials and
stored at 20 °C overnight. LC–MS analysis was performed
as described above for the analysis of transporter kineticTable 1
Summary of clinical cohorts used for model development; data obtained fr
Age range (years) Dose (mg m2) n Weight
Development set
10–20 0.72 5 51.5 ± 1
1.05 4 75.3 ± 8
1.28 8 49.9 ± 7
1.5 6 45.1 ± 1
Test set
6–<10 0.77 5 31.9 ± 6
1.5 6 29.4 ± 3
1–<6 0.6 11 10.4 ± 1
0.76 7 16.7 ± 3
1.01 16 13.6 ± 2
1.12 8 17.2 ± 4
1.48 14 18.0 ± 3
1.55 11 15.8 ± 3
16 to 53 1 21
0.8 9
4 Br J Clin Pharmacol (2016) •• ••–••samples. The blood-to-plasma ratio was calculated from the
following equation (where Kb/p is the whole blood-to-plasma
partition coefficient, Ke/p is the red blood cell-to-plasma par-
tition and H is the haematocrit):
Blood-to-plasma Kb=pð Þ ¼ Ke=pHð Þ þ 1Hð Þ (1)
Selection of clinical data
Ethical approval for the collection and use of patient data was
obtained as part of the clinical trials involved, as previously
described [6, 8, 10]. Data generated from studies conducted
in the UK were selected for the development of this model
due to the quantity of information available for each individ-
ual subject. The data, previously published by Hill et al. [8],
were initially separated into age groups of 1–<6, 6–<10 and
10–20 years of age. Data were then further categorized into
dose bands, as different dosing regimens had been used. The
banding of the clinical data is detailed in Table 1. Data from
one of the four dose bands in the 10–20-year-old patient age
range were used for model building, as they were the least
likely to be affected by age-related changes, while the remain-
ing three dose bands were used for the model development
set. The data for patients in the 1–<6 and 6–<10 year age
bands were utilized for comparison with the simulated data
obtained from the model. PK data for 30 adult patients were
provided by St Bart’s Hospital, London, for further assess-
ment of the model [6].om [8]
(kg) mean ± SD BSA (m2) mean ± SD % female
4.1 1.5 ± 0.27 40
.0 1.9 ± 0.11 25
.9 1.5 ± 0.15 50
0.1 1.4 ± 0.19 16.7
.6 1.1 ± 0.15 40
.3 1.0 ± 0.09 33
.0 0.5 ± 0.03 55
.3 0.7 ± 0.09 43
.3 0.6 ± 0.07 69
.6 0.7 ± 0.14 27
.8 0.7 ± 0.11 50
.6 0.7 ± 0.10 55
2.0 ± 0.16
2.0 ± 0.14
Actinomycin D PBPK model for children with cancerModelling and simulation
Model development and initial simulations. Modelling and
simulation were performed using Simcyp version 14 release 1
(Simcyp Ltd, a Certara company, Sheffield, UK). The compound
file for Act D was compiled using data generated in the
methods described above and with additional inputs from web
databases and literature sources as shown in Table 2. The
Simcyp software provides a framework for assessing the PK of a
drug by defining certain characteristics within a compound file.
Using this compound file, pharmacokinetic data can then be
simulated in individuals of a virtual population of interest,
allowing for the impact of inter-individual differences to be
assessed [17, 18].
For the simulation of clinical trial data, information was
taken fromprevious work byHill et al., who studied 117 patients
administered Act D intravenously [8]. The population was split
into three age categories: 1–<6 (n = 67), 6–<10 (n = 11) and
10–20 years (n = 39). These age bins were further subdivided
based on the dose of Act D received (Table 1). Simulations were
run over 26 h following an IV bolus dose (relative to body sur-
face area) administered over 3 min. A learn-and-confirm ap-
proach to model development was implemented, with initial
simulations performed in a subset of the 10–20-year-old age
range receiving the 1.24 mg kg1 dose, using 10 trials of 10 vir-
tual individuals, with half of the virtual population as females.
These initial simulations were performed using the data shown
in Table 2 with no fitting of parameters. Subsequent changes
to parameters made during the development of the model are
described in the results section.
In order to replicate the volume of distribution seen
clinically, the tissue partition coefficients were set based on
information from dogs [28]. Once these values were incorpo-
rated, the muscle and adipose values were adjusted in order to
fit the observed steady-state volume of distribution from theTable 2
Summary of parameters utilized for the PBPK Act D model development
Parameter Value
Molecular weight 1255.42 (g mol1)
Log P 4.77
Compound type Neutral
Blood/plasma 0.62
Fraction unbound 0.95
Distribution model Method 2
Kp scalar 0.06
Muscle distribution 5.812
Adipose distribution 27.945
CLRenal 1.8 (l h
1)*
CLBiliary 0.107 (μl min
1/106 hepatocytes)*
CLAdditional 3.31 (l h
1)*
*For these clearance values a CV of 60% was used.prior clinical study [8]. Running simulations with these parti-
tion coefficients yielded an initial systemic concentration
comparable to that observed clinically.
As 50% of the accounted clearance of Act D is observed in
faeces, two alternative methods for simulating the active bil-
iary excretion of Act D were evaluated in the model develop-
ment stage:
1 The kinetic data for ABCB1 (MDR1) generated as part of this study
was incorporated into the simulator for biliary transport of drug.
2 The biliary and renal clearance values were taken from a paper
by Tattersall et al. [5]. These data were incorporated into the
PBPK model and used to generate in vitro data using the retro-
grade model. An additional clearance value was estimated
using the parameter estimation function (Nelder–Mead
method) within Simcyp to account for clearance of the drug
that was not recovered.
Final simulations. Further evaluation of the final model was
undertaken using adult PK data [6] made available from St
Bart’s Hospital (London, UK). Ten trials of 10 virtual subjects
each were simulated in the default Caucasian healthy
volunteer population, age range 21–64 years, with a
proportion of females of 0.48. Paediatric simulations were
performed in the 1–<6 and 6–<10 year populations from
the study by Hill et al., with age bin data further subdivided
based on dose. Simulations were performed for all age bands
and doses described in Table 1. The proportion of females
was set as shown in Table 1 and a total of 100 subjects were
simulated for each trial.
Simulations were then run to prospectively predict the
Act D plasma PK profile in very young children. Simulations
of 100 subjects given doses of 1.25 mg m2 were run for three
age groups: 0–<3 months, 3–<6 months and 6–12 months.Reference
http://www.drugbank.ca/drugs/DB00970
Current study
Determined from chemical structure
Current study
http://www.drugbank.ca/drugs/DB00970
Rodgers and Rowland [25]
Determined by fitting using Lutz et al. [28]
Modified from values in Lutz et al. [28]
Modified from values in Lutz et al. [28]
Tattersall et al. [5]
Tattersall et al. [5]
Fitted using parameter estimation – Nelder–Mead method.
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mean and the 5th and 95th percentile for the concentrationtime
profile as well as the calculated mean, median and geometric
mean of the simulated population. Avisual predictive check of
the simulated against observed data was performed on the
final simulated results, including the number of data points
within the 5th and 95th percentiles. In addition, the mean
fold-prediction of AUC against observed data was determined;
a two-fold under- or over-prediction was considered a
reasonable prediction and within 1.5-fold a good prediction.
The prediction of model variability was also assessed in a
similar way by comparing coefficients of variation (CV).Results
Log P
Using the HPLC method described, retention times were
determined for all standards and Act D and k values were
calculated using the following equation (where tr is the reten-
tion time of the compound of interest and t0 is the retention
time of sodium nitrate):
k ¼ tr  t0
t0
(2)
Table 3 provides a summary of the results obtained. As
shown in Figure 1, a correlation was determined between
Log k and the known Log P values for the standards, and the
Log P of Act D was extrapolated from the standard curve ob-
tained. The Log P values for the standard compounds when
determined by interpolation of the standard curve were all
within 30% of their published values. The Log P of Act D
was calculated as 4.47 (Table 2).Transporter kinetics
The Transwell™ assay to characterize the enzyme kinetics of
transport of Act D by ABCB1 (MDR1) determined the maxi-
mum rate of flux (Jmax) to be 1142 μM min
1/106 cells, with
a Michaelis–Menten constant (Km) of 20 μM. Figure 2 shows
the rate of efflux vs. Act D concentration curve which appears
to have reached a plateau by 100 μM.Table 3
Retention times of standard compounds and Act D and values used to dete
Compound Retention time (min) k Log k E
Phenol 0.81 0.75 -0.13 1
Dexamethasone 0.97 1.10 0.04 1
Chloramphenicol 0.77 0.66 -0.18 1
Verapamil 4.19 80.2 0.90 3
Act D 13.94 28.72 1.46 4
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Concentrations of Act D in blood cells compared to concen-
trations in plasma were determined after spiking whole blood
with drug concentrations ranging from 0.2 to 10 μg ml1.
Blood-to-plasma ratios between 0.59 and 0.65 were observed,
with a mean blood-to-plasma ratio of 0.62 determined (95%
confidence interval 0.03). This ratio was not dependent on
Act D concentration.Simulations
Drug data for the compound file were taken from sources
online and from the experiments detailed in this paper.
Initial simulations were performed with the compound
file data, including ABCB1 (MDR1) as a canalicular trans-
porter in the liver, with no fitting. However, this resulted
in an over-prediction of the biliary elimination and a sub-
sequent AUC that was lower than that derived from the
clinical data.
The final drug model incorporated clinical renal and biliary
clearance values and an additional systemic clearance value to
account for the differences observed in cumulative renal/biliary
clearance and total observed systemic clearance (see Table 2
for values). Simulations using these clearance values were
superimposed on the observed data (Figure 3A). Comparison of
AUC0-26h in observed and simulated patients within the 10–20-
year-old group showed allmeanpredictions to bewithin two-fold
of the mean observed values. The fold variability compared to
observed values ranged from 1.2-fold to 1.6-fold, depending on
dose group (Figure 3B). The model prediction was compared to
data obtained from an adult PK study dataset [6]. The visual
predictive check (Figure 4) showed that the simulated mean
concentration–time profile fell within the observed results;
however, the simulation failed to capture the full variability of
the observed data (observed AUC0-26h SD: 595.33 ng h ml
1,
simulated AUC0-26h SD: 9.04 ng h ml
1).
For the younger age ranges (example profile, Figure 3B),
all AUC predictions were within two-fold of the observed
values, with simulated data from six of the eight age/dose
ranges falling within 15% of the observed data (Table 4).
The level of variability as compared to the observed values
ranged from 1- to 1.8-fold. Simulations for very young children
(0–<3, 3–<6 and 6–12 months old) showed comparable PK
profile shape to the older children, with mean AUC0-26h values
of 104.07, 109.99 and 115.42 ng h ml1 and clearance values
of 3.5, 3.6 and 3.8 l h1 determined, respectively (Figure 5).rmine the Log P of Act D
xperimental Log P Literature Log P Reference
.49 1.47 (Hansch et al., [26])
.80 1.83 (Lombardo et al. [27])
.38 1.14 (Lombardo et al. [27])
.45 3.79 (Hansch et al. [26])
.47 —
Figure 4
Systemic concentration of Act D vs. time for 21 adult clinical
patients (circles) and mean (black line), 5th and 95th percentile
(grey lines) of the simulated patient systemic Act D concentration
over time, 16–53 year old administered 1 mg m2
Figure 1
Standard curve of compounds with known Log P values. From left to
right, the compounds are: 4-methoxyphenol, m-cresol, 1-naphthol,
thymol, diphenyl ether
Figure 2
Graph showing the rate of movement of Act D across the MDCKII-
MDR1 monolayer at various concentrations
Figure 3
Visual predictive check showing the systemic concentration of Act D
vs. time for clinical patients (circles) and mean (black line), 5th and
95th percentile (grey lines) of the simulated patient systemic Act D
concentration. (A) Simulated and mean study patient Act D systemic
concentration over time, 10–20 year old administered 1.29 mgm2;
(B) Simulated and mean study patient Act D systemic concentration
over time, 1–6 year old administered 0.6 mg m2
Actinomycin D PBPK model for children with cancerDiscussion
The current study describes the development of a PBPKmodel
for the prediction of Act D exposure in children using a com-
bination of experimentally determined and literature-derived
system parameters. The model described shows an ability to
predict the systemic exposure of Act D across a range of ages
and doses, with all simulated AUC values falling within
two-fold and in six out of eight cases within 15% of those ob-
served in clinical pharmacokinetic studies. Themodel has the
potential to be used for the prediction of Act D exposure in
very young cancer patients, including neonates and infants
less than one year old, and may help guide future dosing in
a clinical setting. Ultimately, however, independent data
from neonates and infants will be required for full validation
of this model, especially in children less than one year of age
in whom virtually no Act D PK data exist. Indeed, this reflects
a wider problem in cancer therapy, with PK data in neonates
and very young infants being extremely difficult to obtain butBr J Clin Pharmacol (2016) •• ••–•• 7
Table 4
Comparison of AUC0-26h observed clinically and simulated for patients of different ages and doses
Age group
(years) Dose (mg m2)
Mean simulated
AUC (ng h ml1) ± SD
Mean observed AUC
(ng h ml1) ± SD
Simulated/
Observed ± SD
10–20* 0.74 57 ± 11 45 ± 8 1.27 ± 0.33
1.04 77 ± 16 50 ± 12 1.54 ± 0.49
1.48 118 ± 25 120 ± 44 0.98 ± 0.42
6–<10 0.77 67 ± 11 80 ± 28 0.84 ± 0.32
1.50 130 ± 21 130 ± 12 1.00 ± 0.19
1–<6 0.60 57 ± 12 82 ± 18 0.70 ± 0.21
0.76 72 ± 15 63 ± 8 0.14 ± 0.28
1.01 94 ± 20 71 ± 33 1.32 ± 0.68
1.12 106 ± 23 82 ± 16 1.29 ± 0.38
1.48 136 ± 30 111 ± 16 1.22 ± 0.32
1.55 146 ± 33 128 ± 51 1.14 ± 0.52
*The 10–20-year-old group was used to determine the best level at which to set the variability.
C. Walsh et al.urgently needed if PBPK models are to be used with confidence
to guide dosing in this most vulnerable population. This holds
true for virtually all anticancer drugs used in neonates and in-
fants. With the recent revocation of paediatric investigation
plan waivers for a number of drug classes, PBPK modelling has
the potential to be of use, informing initial dose selection and
trial design for these drugs [29].
Although this PBPK model for Act D accurately predicts
the mean values of the adult data profiles, it failed to capture
the full variability observed in the adult PK dataset. One
reason for this may be that while the CLRenal was determined
mechanistically as described in the methods section, the
variability of biliary and additional clearances in the model
within Simcyp were determined by the %CV entered into
the compound file. This was set at 60% based on the variabil-
ity seen in the development population of 10–20 year oldsFigure 5
Systemic concentration of Act D vs. time for 100 simulated patients
less than one year of age given 1.25 mg m2 IV mean, 5th and
95th (0–<3 months, 3–<6 months, 6–12 months)
8 Br J Clin Pharmacol (2016) •• ••–••given the relatively small set of data used for development.
This may under-estimate the true variability of Act D PK in
the Caucasian adult population. Another factor is the impact
of co-administered drugs such as vincristine. As 90% of
patients were receiving both Act D and vincristine, it was
not possible to determine any impact of co-administration.
In addition, healthy virtual adult and also paediatric popula-
tionswere used in this study. These populations donot necessar-
ily reflect physiological changes occurring in the setting of
cancer which can affect drug disposition. Such changes may
include increased alpha 1 acid glycoprotein and decreased albu-
min concentrations [30] as well as increases in inflammatory
markers which may suppress enzyme and transporter function
[31, 32], decreases in GFR after nephrotoxic drug treatments,
and bodymass alterations due to cachexia. These changes could
have a direct impact on the PK of any drugs given to patients
with existing conditions.
These same physiological changes occurring in the paedi-
atric cancer population are complicated by the known effects
of age and development in all paediatric populations on fac-
tors such as renal function, plasma protein concentrations,
enzyme and transporter expression, body surface area, and
organ size and blood flow [17]. Analysis of demographic and
laboratory data from childhood cancer patients is currently
being undertaken with a view towards characterizing the dif-
ferences between ontogeny functions in paediatric cancer pa-
tients as compared with healthy children and building a
virtual paediatric cancer population for use in PBPK model-
ling and simulation in paediatric cancer [33].
In addition, it is also feasible that Act D disposition in
humans has not been fully characterized and therefore un-
known mechanisms of clearance or transport may exist that
could not be incorporated into the model. It has been sug-
gested that Act D binds to DNA at specific regions [1], hence
it is possible that irreversible binding of Act D to DNAmay re-
flect a clearance pathway that has not yet been elucidated.
Actinomycin D PBPK model for children with cancerFurther research into the clearance of Act D and how it
changes with age may help increase confidence in these pre-
dictive simulations.
Finally, a greater understanding of the specific transporters
involved in the clearance of Act D is required, as well as an im-
proved knowledge of the absolute expression and activity of
those transporters in the relevant tissues and their ontogeny.
The availability of these data would clearly help with the devel-
opment of future PBPK models in paediatric oncology.
The ability of themodel described to predict Act D AUC in
a variety of paediatric age ranges suggests that it is possible to
develop PBPK models for anticancer drugs in populations
where minimal datasets exist. As was the case in the current
study, such approaches may require the generation of physio-
chemical and in vitro drug information not available through
published literature and database searches. As more informa-
tion on ontogeny of physiological processes becomes avail-
able, predictive PK models have the potential to improve
chemotherapy dosing for the youngest patients who may be
most at risk of adverse effects following treatment. PBPK also
provides the scope to investigate specific tissue distribution
of drugs as well as to incorporate new data both in the form
of model specification or physiological data, without the
need to perform further clinical trials.Competing Interests
All authors have completed the Unified Competing Interest
form at http://www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare no support
from any organization for the submitted work. Dr Trevor John-
son and Dr Sibylle Neuhoff are employees of Simcyp Ltd (a
Certara Company). Simcyp’s research is funded by a consortium
of pharmaceutical companies. The Simcyp Simulator is freely
available, following completion of the trainingworkshop, to ap-
proved members of academic institutions and other not-for-
profit organizations for research or teaching purposes. The au-
thors have no other relationships or activities that could appear
to have influenced the submitted work.
This work was supported in part by the Medical Research
Council, the NIHR Newcastle Biomedical Research Centre
and Cancer Research UK.Contributors
CW carried out the experimental work outlined in the paper
and development of the PBPKmodel. JB, TJ, SH, AB andGVpro-
vided input into the model development and assistance with
manuscript preparation. EG and JGwere responsible for the pro-
vision of clinical data from the adult clinical trial. All authors
read and approved the final version of the manuscript.References
1 Goldberg IH, Rabinowitz M, Reich E. Basis of actinomycin action.
I. DNA binding and inhibition of RNA-polymerase syntheticreactions by actinomycin. Proc Natl Acad Sci U S A 1962; 48:
2094–101.
2 White L, Tobias V, Hughes DW. Actinomycin D-induced
hepatotoxicity. Pediatr Hematol Oncol 1989; 6: 53–7.
3 Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W.
Age is a risk factor for chemotherapy-induced hepatopathy with
vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol
2004; 22: 1894–901.
4 Bisogno G, de Kraker J, Weirich A, Masiero L, Ludwig R, Tournade
MF, Carli M. Veno-occlusive disease of the liver in children treated
for Wilms tumor. Med Pediatr Oncol 1997; 29: 245–51.
5 Tattersall MH, Sodergren JE, Sengupta SK, Trites DH, Modest EJ,
Frei E III. Pharmacokinetics of actinomycin D in patients with
malignant melanoma. Clin Pharmacol Ther 1975; 17: 701–8.
6 Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa
K, Wilson P, Asterling S, Liu S, Wyatt P, Joel SP, Oliver RT. GAMEC –
a new intensive protocol for untreated poor prognosis and
relapsed or refractory germ cell tumours. Br J Cancer 2007; 97:
308–14.
7 Galbraith WM, Mellett LB. Tissue disposition of 3 H-actinomycin
D (NSC-3053) in the rat, monkey, and dog. Cancer Chemother
Rep 1975; 59: 1601–9.
8 Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ.
Characterisation of the clinical pharmacokinetics of actinomycin
D and the influence of ABCB1 pharmacogenetic variation on
actinomycin D disposition in children with cancer. Clin
Pharmacokinet 2014; 53: 741–51.
9 Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M,
Veal GJ, Boddy AV, Adamson PC, Barrett JS. Population
pharmacokinetic investigation of actinomycin-D in children and
young adults. J Clin Pharmacol 2008; 48: 35–42.
10 Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, Howe K,
Chisholm JC, Beane C, Brennan B, Waters F, Glaser A, Hemsworth
S, McDowell H, Wright Y, Pritchard-Jones K, Pinkerton R, Jenner
G, Nicholson J, Elsworth AM, Boddy AV, Kingdom Children’s
Cancer Study Group Pharmacology Working Group.
Pharmacokinetics of dactinomycin in a pediatric patient
population: a United Kingdom Children’s Cancer Study Group
study. Clin Cancer Res 2005; 11: 5893–9.
11 Gurney JG, Smith MA, Smith JA. Cancer among infants. In:
Cancer Incidence and Survival among Children and Adolescents:
United States SEER Program 1975-1995, eds Ries GLA, Smith MA,
Gurney JG, Linet M, Tamra T, Young JL, Bunin GR. Bethesda, MD:
National Cancer Institute, SEER Program NIH Pub No 99-4649,
1999; 149–56.
12 Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A,
Arndt CA. Dactinomycin and vincristine toxicity in the treatment of
childhood cancer: a retrospective study from the Children’s Oncology
Group. Pediatr Blood Cancer 2011; 57: 252–7.
13 Tournade MF, Com-Nougue C, de Kraker J, Ludwig R, Rey A,
Burgers JM, Sandstedt B, Godzinski J, Carli M, Potter R, Zucker JM.
Optimal duration of preoperative therapy in unilateral and
nonmetastatic Wilms’ tumor in children older than 6 months:
results of the Ninth International Society of Pediatric Oncology
Wilms’ Tumor Trial and Study. J Clin Oncol 2001; 19: 488–500.
14 Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A,
Rowland-Yeo K. A mechanistic framework for in vitro-in vivo
extrapolation of liver membrane transporters: prediction of drug–
drug interaction between rosuvastatin and cyclosporine. Clin
Pharmacokinet 2014; 53: 73–87.Br J Clin Pharmacol (2016) •• ••–•• 9
C. Walsh et al.15 Neuhoff S, Gaohua L, Burt H, Jamei M, Li L, Tucker GT, Rostami-
Hodjegan A. Accounting for transporters in renal clearance:
towards a mechanistic kidney model (Mech KiM). In:
Transporters in Drug Development: Discovery, Optimization,
Clinical Study and Regulation, eds Sugiyama Y, Steffansen B. New
York: Springer, 2013; 155–77.
16 Jiang X, Zhao P, Lesko LJ, Schmidt S. Application of
physiologically-based pharmacokinetic (PBPK) model in
predicting drug metabolism and pharmacokinetics in pediatric
populations – a case study of acetaminophen. Clin Pharmacol
Ther 2013; 93: S8.
17 Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the
clearance of eleven drugs and associated variability in neonates,
infants and children. Clin Pharmacokinet 2006; 45: 931–56.
18 Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-
Hodjegan A. A semi-mechanistic model to predict the effects of
liver cirrhosis on drug clearance. Clin Pharmacokinet 2010; 49:
189–206.
19 Adam K, Schmiedl S, Szymanski J, Imschweiler T, Voelpel S, Niehues
T, Sinha K, Wirth S, Abuhejleh A,Willmann S, Lippert J, Thuermann
PA. Evaluation of the physiology-based pharmacokinetic (PBPK)
model PK-SIM in children receiving high-dose methotrexate. Basic
Clin Pharmacol Toxicol 2009; 105: 129–30.
20 Kersting G, Willmann S, Wurthwein G, Lippert J, Boos J, Hempel
G. Physiologically based pharmacokinetic modelling of high- and
low-dose etoposide: from adults to children. Cancer Chemother
Pharmacol 2012; 69: 397–405.
21 Alexander SP, Mathie A, Peters JA. Guide to Receptors and
Channels (GRAC), 5th edition. Br J Pharmacol 2011; 164: S1–324.
22 Zhao Y, Jona J, ChowDT, RongH, SeminD,Xia X, ZanonR, Spancake
C, Maliski E. High-throughput logP measurement using parallel
liquid chromatography/ultraviolet/mass spectrometry and sample-
pooling. Rapid Commun Mass Spectrom 2002; 16: 1548–55.
23 Hill CR, Jamieson D, Thomas HD, Brown CD, Boddy AV, Veal GJ.
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and
ABCG2 in the transport and pharmacokinetics of actinomycin D
in vitro and in vivo. Biochem Pharmacol 2013; 85: 29–37.10 Br J Clin Pharmacol (2016) •• ••–••24 Veal GJ, Errington J, Sludden J, Griffin MJ, Price L, Parry A, Hale J,
Pearson AD, Boddy AV, Group UPW. Determination of anti-cancer
drug actinomycin D in human plasma by liquid chromatography-
mass spectrometry. J Chromatogr B Analyt Technol Biomed Life
Sci 2003; 795: 237–43.
25 Rodgers T, Rowland M. Mechanistic approaches to volume of
distribution predictions: understanding the processes. Pharm Res
2007; 24: 918–33.
26 Hansch C, Leo A, Hoekman D. Exploring QSAR - Hydrophobic,
Electronic, and Steric Constants. Washington, DC: American
Chemical Society 1995; p. 20.
27 Lombardo F, Shalaeva MY, Tupper KA, Gao F. ElogDoct: A tool for
lipophilicity determination in drug discovery. 2. Basic and
neutral compounds (2001) Journal of Medicinal Chemistry, 14:
2490–97.
28 Lutz RJ, Galbraith WM, Dedrick RL, Shrager R, Mellett LB. A
model for the kinetics of distribution of actinomycin-D in the
beagle dog. J Pharmacol Exp Ther 1977; 200: 469–78.
29 Jones HM, Mayawala K, Poulin P. Dose selection based on
physiologically based pharmacokinetic (PBPK) approaches. AAPS
J 2013; 15: 377–87.
30 Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically
based pharmacokinetic (PBPK) approach to evaluate
pharmacokinetics in patients with cancer. Biopharm Drug Dispos
2013; 34: 141–54.
31 Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A
drugmetabolism is reduced in cancer patients who have an acute-
phase response. Br J Cancer 2002; 87: 277–80.
32 Sukhai M, Yong A, Pak A, Piquette-Miller M. Decreased expression
of P-glycoprotein in interleukin-1beta and interleukin-6 treated
rat hepatocytes. Inflamm Res 2001; 50: 362–70.
33 Bonner J, Walsh C, Johnson T, Neuhoff S, Greystoke A, Veal G.
Building of a paediatric cancer population for physiologically-
based pharmacokinetic modelling and simulation in neonates,
infants and children. Abstracts of the Annual Meeting of the
Population Approach Group in Europe, 2015.
